Kornimate/medical-research-clean huggingface dataset:
fitbit study on mobility and readmissions after radical cystectomy

Conditions: Bladder Cancer

Summary: this is a two-arm randomized, controlled trial during the postoperative period after major abdominal surgery for cancer, including for example radical cystectomy, nephrectomy, colectomy, comparing a control group that uses a wearable device to track physical activity to an intervention group that uses the same wearable devices and receives a supportive social incentive-based gamification intervention to adhere to a step goal program.

we will conduct a two-arm randomized, controlled trial during the postoperative period after a radical cystectomy for bladder cancer, comparing a control group that uses a wearable device to track physical activity to an intervention group that uses the same wearable devices and receives a supportive social incentive-based gamification intervention to adhere to a step goal program. patients will be enrolled after being diagnosed with bladder cancer and scheduled to undergo a radical cystectomy. the median length of stay after a radical cystectomy is 8 days, with 90% being discharged within two weeks. postoperatively, the baseline step count will be averaged by taking the steps taken during the first two days outside of the intensive care unit. there will be two postoperative phases: phase i will be while the patient is hospitalized postoperatively. phase ii will be when the patient is discharged for three months. 5.2 study

Eligibility criteria:
inclusion criteria: * age 18 years or older * diagnosis of cancer undergoing definitive surgical treatment exclusion criteria: * inability to provide consent * does not have daily access to a smartphone compatible with the wearable device and not willing to use a device that the investigators can provide them * any other medical conditions that would prohibit participation in a physical activity program
effect of omega 3 fatty acids on lactation period

Conditions: Lactation Induced

Summary: the world health organization (who) and the united nations children's fund (unicef) recommend that babies be exclusively breastfed for the first 6 months from birth. the composition of breast milk is dynamic and may vary according to the content of maternal nutrition. maternal nutrition, on the other hand, determines the quality of breast milk necessary for the adequate growth and health of infants. for this reason, the content of the maternal diet is important during the lactation period, which is the critical stage that can affect the development of infants. omega 3 fatty acids are essential unsaturated fatty acids that are not synthesized by the human body and must be obtained through diet. the polyunsaturated fatty acids (pufas) most abundant in the diet are short-chain omega 3 alpha linolenic acid (ala) and omega 6 linoleic acid (la), which are mostly found in vegetable oils. ala is a plant-derived omega 3 fatty acid found in flaxseed, walnut, canola and soybean oils. eicosapentaenoic acid (epa) and docosahexaenoic acid (dha) are found in marine sources such as seafood and fish oils. today, the use of omega 3 fatty acid supplements is increasing during the lactation period. however, consumption of omega 3 fatty acid sources during pregnancy or lactation is thought to be an important factor in preventing cancer risk. in our study, the investigators aimed to compare the maternal diet and the consumption of fish oil, flaxseed oil and walnut oil supplements during the lactation period, to compare the amount of prolactin and dha in the milk composition and to compare the protective effects against breast cancer with cancer stem cell markers. for this study, 32 healthy wistar pregnant rats, weighing 200-250 g, 8-10 weeks pregnant and not included in any experiments, will be used. supplementary oils will be administered by oral gavage, considering the 0.5 g/kg body weight of the pregnant rats according to the groups they are assigned to, during the entire standard lactation period (day 21), considering the day of birth of the pregnant rats as the 0th day of lactation. mother rats will be sacrificed under anesthesia at the end of the 21st day of lactation, mammary tissues will be taken into appropriate solutions and histopathological and immunohistochemical examinations will be performed. in addition, cardiac blood will be drawn and blood and tissue biochemical analyzes will be performed.


Eligibility criteria:
inclusion criteria: * healthy rats exclusion criteria: * patient rats * rats that cannot be gavaged

Keywords: lactation omega 3 fatty acid fish oil flaxseed oil walnut oil breast cancer
effects of 1:1 inspiratory to expiratory ratios on oxygenation and intrapulmonary shunt fraction during one lung ventilation in the obese patients

Conditions: Obese Patients, One Lung Ventilation

Summary: one-lung ventilation, even in patients with healthy weight, causes an impairment in gas-exchange and respiratory mechanics. we hypothesized that oxygenation during the one-lung ventilation in obese patients would be improved by applying inverse-ratio ventilation, reducing atelectasis in the dependent lung and resulting in reduced shunt. because of the restrictive ventilatory effects of obesity, these patients often show a decreased functional residual capacity and decreased expiratory reserve volume, leading to an overall decreased tidal volume. these reduction leads to arterial hypoxemia, v-q mismatch and rt to lt shunting. there are few studies on the one lung ventilation in obese patients about this prolonged inspiratory time ventilatory method. we plan to investigate the effect of this ventilation method in obese patients during one lung ventilation.


Eligibility criteria:
inclusion criteria: 1. above 40 years of age. 2. american society of anesthesiologists (asa) physical status i, ii, iii. 3. obesity (bmi \>25 kg/ m2 ) 4. thoracic surgical procedure exclusion criteria: 1. severe functional liver or kidney disease 2. diagnosed hf ( nyha class \>3) 3. reduced pulmonary diffusion capacity \< 80%
early dvc ligation and urinary continence recovery after rarp

Conditions: Prostate Cancer

Summary: the aim of the study is to evaluate the impact of early deep venous complex ligation (edvcl) in patients affected by clinically localized prostate cancer (pca) undergoing robot-assisted radical prostatectomy with or without pelvic lymph node dissection. overall, 312 patients will be randomized to the standard technique vs. edvcl. the primary endpoint is represented by early urinary continence recovery. the secondary endpoints are perioperative outcomes, erectile function recovery and positive surgical margins.


Eligibility criteria:
inclusion criteria: 1. male patients, aged between 18 and 80 years old 2. planned to receive robot-assisted radical prostatectomy for prostate cancer 3. able to understand and willing to sign a written informed consent document 4. on stable dose of current regular medication for at least 4 weeks prior to trial entry exclusion criteria: the participant may not enter the trial if any of the following apply: 1. life expectancy of less than 12 months 2. previous chemotherapy 3. previous brachytherapy or external beam radiotherapy 4. preexisting urinary incontinence defined as 1 or more pads per day 5. unstable cardiovascular disease 6. congestive heart failure (chf) 7. clinically significant hepatobiliary or renal disease 8. history of significant cns injuries within 6 months 9. any other significant disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial

Keywords: prostate cancer radical prostatectomy deep venous complex ligation
zero fluoroscopic ablation versus conventional fluoroscopic ablation for right atrial arrhythmias

Conditions: Atrial Arrhythmia; Atrial Premature Complexes; Atrial Tachycardia

Summary: this study is intended to compare the feasibility, safety and efficacy of a zero-fluoroscopic approach with conventional fluoroscopic approach as performing catheter ablation of right atrial arrhythmias.

catheter ablation is a well-established treatment to treat patients with a wide range of heart rhythm disturbances. fluoroscopy is the imaging modality routinely used for cardiac device implantation and electrophysiological procedures. due to the rising concern regarding the harmful effects of radiation exposure to both the patients and operation staffs, novel three-dimensional mapping systems such as ensite navx have been developed and implemented in electrophysiological procedure for the navigation of catheters inside the heart chambers. ensite navx is a promising system to guide catheters inside the cardiac chambers and vessels without the use of fluoroscopy. this study is intended to compare the feasibility, safety and efficacy of a zero-fluoroscopic approach with conventional fluoroscopic approach as performing catheter ablation of right atrial arrhythmias.

Eligibility criteria:
inclusion criteria: * atrial tachycardia * atrial premature complexes exclusion criteria: * left atrial premature complexes * left atrial tachycardia

Keywords: fluoroscopy ablation three dimensional atrial arrhythmia radiation
does asthma phenotype have impact on disease control

Conditions: Asthma

Summary: the application of biomarkers that are more closely associated with eosinophillic airway inflammation, such as measurements of feno level, cell count in induced sputum or bronchial reactivity could improve asthma control by better directing treatment. a systematic review and meta-analysis is to be conducted to assess the efficacy of tailoring asthma intervention on clinical symptoms compared with exhaled nitric oxide or induced sputum count.

ahr used as outcome

Eligibility criteria:
inclusion criteria: * positiv mannitol * asthma diagnose exclusion criteria: * other lung disease
platelet modulation: a study of angiogenic and coagulation proteins in patients with cancer

Conditions: Cancer

Summary: blood samples on persons with cancer will be sampled for angiogenic, metastatic and coagulation proteins.


Eligibility criteria:
inclusion criteria: * patients with a diagnosis of malignancy exclusion criteria: * patients taking aspirin, nsaids, warfarin or platelet inhibitor therapy

Keywords: breast cancer platelets metastatic cancer malignancy
ultrasound and photoacoustic imaging for cervical cancer

Conditions: Cervical Cancer; Cancer of the Cervix

Summary: the investigators have developed co-registered transvaginal photoacoustic and ultrasound (us) imaging techniques that allow them to visualize ovarian tumor structure and functional changes simultaneously, which may potentially reveal early tumor angiogenesis development or residual tumors after systemic treatment that is not available by us alone. the ability to detect early angiogenesis changes, as well as tumor morphology changes using a non-invasive imaging modality will greatly enhance the care for patients. the investigators plan to explore these techniques in monitoring cervical cancer treatment response and conduct pilot feasibility studies.


Eligibility criteria:
* diagnosis of cervical cancer of any stage that will be treated with radiation therapy and concurrent chemotherapy. * at least 18 years of age. * not pregnant and/or breastfeeding. * able to understand and willing to sign an irb-approved written informed consent document.
post-transplant cyclophosphamide in patients aged >/= 65 years undergoing haploidentical transplant

Conditions: Hematologic Malignancies

Summary: the purpose of this phase 1 study is to determine the optimal dose of the immune suppressive drug, cyclophosphamide, following standard allogeneic stem cell transplant in patients aged \>/= 65 years with hematologic malignancies.

the patients will receive a standard dose, or a reduced amount of the immune suppressive drug, cyclophosphamide, that is routinely administered after the transplant procedure. the following procedures will be performed: cardiac mri scans and/or transthoracic echocardiogram (tte); laboratory tests, geriatric assessments and tests to measure strength and stability. participation in the study is expected to last up to one year with follow-up visits occurring on day +30, day +100, day +180 and day +365 following allogenic stem cell transplant.

Eligibility criteria:
inclusion criteria: * patient age \>/= 65 years * patient and related donor (if applicable) sign the informed consent form for the study. if donor is unrelated, donor does not sign informed consent form and this will not affect recipient study eligibility. * patient meets standard criteria for allogeneic stem cell transplant * patient is deemed suitable to receive flu/tbi 800 conditioning regimen as standard of care transplant * donor is willing to donate peripheral blood stem cells exclusion criteria: * patient has a diagnosis of myelofibrosis * patient has high titer antibodies (\>10,000 mean fluorescent intensity) against one or more donor hla antigens * patient has undergone prior autologous or allogeneic stem cell transplant * inability to collect at least 3 x 10\^6 cd34+ pbscs/kg recipient weight from the donor * requiring sedation for cardiac mris. * prohibited implants and/or devices: * mechanical, magnetic or electrical activated implants (i.e. cardiac pacemakers, neurostimulators and infusion pumps) * ferromagnetic implants and ferromagnetic foreign bodies, such as intracranial, aneurysm clips, shrapnel and intraocular metal chips as these could become dislodged. * subjects with claustrophobia, problems being in enclosed spaces, or inability to lie supine.

Keywords: allogeneic transplantation
gua sha for chronic low back pain in elderly

Conditions: Back Pain

Summary: the purpose of the study is to investigate whether gua sha is an effective modality for relieving chronic low back pain specifically in the aged population by comparing the baseline measures of pain intensity, self-perceived disability, back range of motion, back local muscle stiffness, depression, sleeping quality, quality of life, biomarkers measurement, and analgesic intake on days 1 and 7 after a single session of gua sha treatment. in addition, the investigators are going to compare between gua sha and hot pack treatments for the above parameters.

subjects will be randomized to receive firstly either one of the treatment arms, and then crossed over to receive another arm after 30 days washing out period. it is expected that gua sha is 1) effective in reducing the intensity of chronic low back pain in the elderly; 2) effective in helping one or more outcome measures in this study and 3) more effective on relieving the low back pain than hot pack in terms of the outcome measures in this study.

Eligibility criteria:
inclusion criteria: * age 60 or above * self-reported painful restriction of lumbar spine mobility for at least 3 months or self-reported low back pain on at least 5 days a week for at least 3 months * have pain intensity score 40 or above on a 100mm visual analog scale (vas) at baseline exclusion criteria: * prior history of radiculopathy or spinal stenosis or spinal fusion or failed surgery syndrome * having radiating pain below the knee * received the following surgery at the region of treatment in the past 12 months laminectomy, laminotomy or discectomy * serious illness (e.g. malignancy) * having wounds or skin lesions at the region of treatment * having blood pressure at140/90 mmhg or above at baseline * having body mass index (bmi) at 18.5 or lower at baseline (as calculated by the weight in kilograms divided by the square of the height in metres (kg/m2) * having active psychiatric disorders, significant mood disorder or dementia

Keywords: gua sha
ipilimumab +/- vaccine therapy in treating patients with locally advanced, unresectable or metastatic pancreatic cancer

Conditions: Pancreatic Cancer

Summary: research hypothesis: ipilimumab (an antibody that blocks negative signals to t cells) administered alone or in combination with a pancreatic cancer vaccine (allogeneic pancreatic tumor cells transfected with a gm-csf gene), has an acceptable safety profile in subjects with locally advanced, unresectable or metastatic pancreatic adenocarcinoma. primary objective: to determine the safety profile of ipilimumab alone or in combination with a pancreatic cancer vaccine in subjects with locally advanced, unresectable or metastatic pancreatic adenocarcinoma. secondary objectives: * to estimate overall survival (os) which will serve as the primary efficacy signal. * to explore an association of t cell responses and immunological responses with os in patients receiving treatment. * to estimate overall response rate (orr), immune related best overall response rate (irbor), progression free survival (pfs), and duration of response in patients receiving treatment. * to explore an association between immune-related adverse events (iraes) and orr. * to measure tumor marker kinetics (ca 19-9) in patients receiving treatment.


Eligibility criteria:
inclusion criteria: 1. documented cancer of the pancreas who have failed (or are not candidates for) standard therapy 2. ecog performance status of 0 to 1 3. adequate organ function as defined by study-specified laboratory tests 4. must use acceptable form of birth control through the study and for 28 days after final dose of study drug 5. signed informed consent form 6. willing and able to comply with study procedures exclusion criteria: 1. currently have or have history of certain study-specified heart, liver, kidney, lung, neurological, immune or other medical conditions 2. clinical metabolic or laboratory abnormalities defined as grade 3 or 4 of the national cancer institute's (nci's) common terminology criteria for adverse events (ctcae), version 3.0 3. systemically active steroids 4. another investigational product within 28 days prior to receiving study drug 5. major surgery or significant traumatic injury (or unhealed surgical wounds) occurring within 28 days prior to receiving study drug 6. infection with hiv, hepatitis b or c at screening 7. pregnant or lactating 8. conditions, including alcohol or drug dependence, or intercurrent illness that would affect the patient's ability to comply with study visits and procedures

Keywords: pancreatic cancer vaccine immunotherapy antibody ctla-4
insulin- and glucose metabolism in pulmonary arterial hypertension

Conditions: Insulin Resistance

Summary: insulin resistance is a key mechanism in metabolic disorders, which has also been implicated in the development of pulmonary hypertension. in this pilot study, the investigators´ goal is to directly determine insulin sensitivity in idiopathic pulmonary arterial hypertension patients and to compare the results with data from healthy controls.


Eligibility criteria:
inclusion criteria: * signed informed consent form * patients with idiopathic or hereditary pulmonary hypertension / healthy controls exclusion criteria: * premenopausal women * other relevant lung disease * relevant left heart disease * untreated systemic hypertension * diabetes mellitus * pulmonary hypertension other than idiopathic or hereditary form
nephrological outcome and associated congenital anomalies in pediatric patients with horseshoe kidney

Conditions: Horseshoe Kidney

Summary: a retrospective, observational multicentre trial on the nephrological outcome and associated congenital anomalies in children with horseshoe kidney.

congenital abnormalities of the kidney and urinary tract (cakut) represent the main cause of ckd in children. among them, the horseshoe kidney (hsk) represents one of the most frequent and is characterised by the presence of two distinct, functioning kidneys positioned on each side of the spine, fused together at one of the poles. the incidence of this condition is approximately 1 case every 400-600 new births with a prevalence in the male sex with a ratio of 2:1. even though these children aregenerally asymptomatic and the diagnosis is often incidental , some may develop symptoms due to complications, such as infections, nephrolithiasis and urinary tract obstruction. more rarely risks of neoplastic degeneration and renal damage are described following trauma to the abdomen and lumbosacral spine. this condition is also associated in up to a third of cases with other abnormalities: the most frequent affect the urinary tract and genitals; however, abnormalities affecting other organs or systems as well as well-defined syndromic pictures. due to its frequent asymptomatic nature, horseshoe kidney is historically considered a condition with a good prognosis and rarely as a risk factor capable of reducing survival or predisposing the kidney to long-term damage. the primary objective of the study is: to assess the 'nephrological outcome' understood as 'prevalence of patients who developed' and 'survival time free from": chronic renal failure, proteinuria, hypertension nephrolithiasis, uti, renal neoplasms and renal trauma. the secondary objectives of the study are: 1. prevalence of congenital and associated genito-urinary and systemic abnormalities; 2. description of renal anatomical features; 3. assessment of the usefulness of second level radiological investigations (vcug, static renal scintigraphy, ddynamic renal scintigraphy).

Eligibility criteria:
inclusion criteria: * patients with confirmed ultrasound and/or scintigraphic diagnosis of horseshoe kidney; * patients with an age at first assessment of between 0 and 18 years; * obtaining written informed consent. exclusion criteria: * patients with a definitive diagnosis of another form of cakut during the diagnostic pathway.

Keywords: horseshoe kidney congenital anomalies children cakut
diagnostics for the reperfusion injury following mi

Conditions: Reperfusion Injury

Summary: the primary purpose of this study is to correlate new cardiac imaging modalities (2d, 3d echocardiography, contrast echocardiography, strain analysis and cardiac mri) to biochemical parameters as the l-arginine-nitric oxide pathway and inflammatory cascades to characterize the reperfusion injury following myocardial infarction and thus providing a basis for further diagnostic and therapeutic approaches.

by reperfusion of ischemic myocardium further tissue damage occurs (ischemia / reperfusion injury). various contributing mechanisms have been discussed in experimental studies, e.g. disturbances in coronary microcirculation and consecutive induction of inflammatory cascades involving formation of reactive oxygen species. the ischemia / reperfusion injury causes diastolic and regional as well as global systolic dysfunction. the time course of the reperfusion injury within the first hours after reperfusion and its effects on the global geometry of the left ventricle have not been investigated so far. in the present study a comprehensive morphological and functional characterisation of the ischemia / reperfusion injury in the acute phase is performed. new cardiac imaging modalities (2d, 3d echocardiography, contrast echocardiography, strain analysis and cardiac mri)and biochemical parameters including the l-arginine-nitric oxide pathway and inflammatory cascades are applied. hereby morphological and biochemical markers for the functional recovery of myocardial function should be identified.

Eligibility criteria:
inclusion criteria: * patients with acute st elevation myocardial infarction and consecutive percutaneous coronary intervention of the infarct-related artery (first myocardial infarction and recurrent myocardial infarction, as long as infarct-related artery is occluded for the first time) * written informed consent or 30 patients with stable cad (control group 1) or 30 healthy volunteers regarding cardiovascular diseases (control group 2) exclusion criteria: * minors * incompetent persons * pregnant and lactating * moderate to severe renal insufficiency defined by an gfr \< 60 ml/kg/m2 * missing written consent * other reasons complicating a clinical reevaluation and/or coronary angiography

Keywords: myocardial infarction, reperfusion injury, echocardiography, magnetic resonance imaging, inflammation, nitric oxide